Correction: Effect of alirocumab on cataracts in patients with acute coronary syndromes.

Suc, Gaspard; Schwartz, Gregory G.; Goodman, Shaun G.; Jukema, J. Wouter; Manvelian, Garen; Poulouin, Yann; Pordy, Robert; Scemama, Michel; Szarek, Michael; Steg, Ph.Gabriel

Baseline characteristics of these patients included mean age 59 years, male sex (81%), diabetes (33%); and mean body mass index 27.3 kg/m2, LDL-C 2.0 mmol/L, lipoprotein (a) B 18.8 b mg/dL, and apolipoprotein A1 B 129.9 b mg/dL. The second paragraph in page 4 should read: A total of 4305 patients in the alirocumab group had >= 2 consecutive LDL-C values < 25 mg/dL (0.65 mmol/L) and were matched to 4305 patients from the placebo group with similar baseline characteristics (Tables 2 and 3). A total of 782 patients in the alirocumab group had >= 2 consecutive LDL-C values < 15 mg/dL (0.39 mmol/L) and were matched to 2346 patients from the placebo group with similar baseline characteristics (Tables 4 and 5).

ACUTE coronary syndrome; CATARACT; HDL cholesterol; LDL cholesterol

BMC Ophthalmology, 2023, Vol 23, Issue 1, p1

1471-2415

Academic Journal

10.1186/s12886-023-03065-2